---
schema_version: "secwatch.filing_event.v1"
accession: "0001601485-25-000108"
form_type: "8-K"
ticker: "ELTX"
cik: "0001601485"
company_name: "Elicio Therapeutics, Inc."
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T17:36:30.963777+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Elicio Q2 net loss $10.6M; IDMC positive for ELI-002 Phase 2; DFS readout Q4 2025

## Summary
- IDMC recommended continue ELI-002 Phase 2 pancreatic study without modification; final DFS analysis expected Q4 2025.
- Net loss $10.6M in Q2 2025 vs $7.2M in Q2 2024; R&D expense decreased to $7.0M.
- Cash $22.1M at June 30, 2025; secured $10M non-dilutive financing in Q2 2025.
- Company expects cash to fund operations into Q1 2026, beyond Phase 2 final analysis.

## SEC filing metadata
- accession: 0001601485-25-000108
- form_type: 8-K
- ticker: ELTX
- cik: 0001601485
- company_name: Elicio Therapeutics, Inc.
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1601485/000160148525000108/0001601485-25-000108-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1601485/000160148525000108/angn-20250807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001601485-25-000108
- JSON: https://secwatch.observer/filing/0001601485-25-000108.json
- Plain text: https://secwatch.observer/filing/0001601485-25-000108.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.